Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Harmony Biosciences Holdings ( (HRMY) ) just unveiled an announcement.
Harmony Biosciences Holdings, a pharmaceutical company, announced strong preliminary net revenues for 2024 and set optimistic revenue guidance for 2025, highlighting its robust pipeline with significant catalysts expected each quarter. The company projects 2025 net revenue between $820 million and $860 million, driven by potential developments in its neuroscience portfolio, including FDA decisions and pivotal trial results, positioning it for long-term growth and stakeholder benefits.
More about Harmony Biosciences Holdings
YTD Price Performance: -2.78%
Average Trading Volume: 740,339
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.93B
For detailed information about HRMY stock, go to TipRanks’ Stock Analysis page.